Roche cervical hopes spring for Avastin but glioblastoma still murky
This article was originally published in Scrip
Executive Summary
More work is needed to define the value of Roche's Avastin (bevacizumab) in newly diagnosed glioblastoma say experts after the publication of two major studies in this setting, but a third study shows that the VEGF inhibitor can significantly extend the lives of women with advanced cervical cancer, a potential new indication.